公开(公告)号：US10988540B2

公开(公告)日：2021-04-27

申请号：US16905211

申请日：2020-06-18

Applicant: OSAKA UNIVERSITY

Inventor： Naoki Hosen ,  Haruo Sugiyama ,  Atsushi Kumanogoh ,  Junichi Takagi

IPC: C07K16/00 ,  C07K16/46 ,  C07K16/28 ,  A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K19/00 ,  A61P35/00 ,  C07K16/30

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US10449144B2

公开(公告)日：2019-10-22

申请号：US14166932

申请日：2014-01-29

Applicant: NITTO DENKO CORPORATION ,  OSAKA UNIVERSITY

Inventor： Katsuyuki Okubo ,  Yoshiki Maeda ,  Arimichi Okazaki ,  Daisuke Asari ,  Takuya Shishido ,  Mitsuhiko Hori ,  Haruo Sugiyama

IPC: A61K9/00 ,  A61K38/10 ,  A61K39/00

Abstract: The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.

公开(公告)号：US10071051B2

公开(公告)日：2018-09-11

申请号：US14166950

申请日：2014-01-29

Applicant: NITTO DENKO CORPORATION ,  OSAKA UNIVERSITY

Inventor： Katsuyuki Okubo ,  Yoshiki Maeda ,  Arimichi Okazaki ,  Daisuke Asari ,  Takuya Shishido ,  Mitsuhiko Hori ,  Haruo Sugiyama

IPC: A61K9/00 ,  A61K38/10 ,  A61K39/00 ,  A61K31/045 ,  A61K31/437 ,  A61K31/451 ,  A61K31/513 ,  A61K31/708 ,  A61K31/716 ,  A61K31/728 ,  A61K31/739

CPC classification number: A61K9/0014 ,  A61K31/045 ,  A61K31/437 ,  A61K31/451 ,  A61K31/513 ,  A61K31/708 ,  A61K31/716 ,  A61K31/728 ,  A61K31/739 ,  A61K38/10 ,  A61K39/0011 ,  A61K2039/54

Abstract: The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof.

公开(公告)号：US20230357390A1

公开(公告)日：2023-11-09

申请号：US18356489

申请日：2023-07-21

Applicant: OSAKA UNIVERSITY

Inventor： Naoki Hosen ,  Haruo Sugiyama ,  Atsushi Kumanogoh

IPC: C07K16/28 ,  C07K16/30 ,  C07K19/00 ,  A61P35/00 ,  C12N15/62

CPC classification number: C07K16/28 ,  C07K16/3061 ,  C07K16/2896 ,  C07K19/00 ,  A61P35/00 ,  C12N15/62 ,  C07K2317/734 ,  C07K2317/34 ,  C07K2317/33 ,  A61K2039/505

Abstract: Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.

公开(公告)号：US10654931B2

公开(公告)日：2020-05-19

申请号：US15751574

申请日：2016-08-02

Applicant: OSAKA UNIVERSITY

Inventor： Naoki Hosen ,  Haruo Sugiyama ,  Atsushi Kumanogoh ,  Junichi Takagi

IPC: C07K16/28 ,  A61K39/00 ,  C07K19/00 ,  C12N5/10 ,  C12N5/09 ,  A61K35/17 ,  C12N15/09 ,  A61P35/00 ,  C07K16/30

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US10899790B2

公开(公告)日：2021-01-26

申请号：US16347337

申请日：2017-11-08

Applicant: OSAKA UNIVERSITY ,  KNC LABORATORIES CO., LTD.

Inventor： Haruo Sugiyama ,  Fumihiro Fujiki ,  Masahiro Neya ,  Shinya Kohno

IPC: C07J63/00 ,  A61P35/00 ,  A61K31/16 ,  A61K31/166 ,  A61K31/196 ,  A61K31/215 ,  A61K31/216 ,  A61K31/265 ,  A61K31/27 ,  A61K31/40 ,  A61K31/445 ,  A61K31/5375 ,  C12N5/0783 ,  A61K31/19 ,  A61P37/04 ,  A61P31/00 ,  A61K31/44

Abstract: Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious disease; a cancer immunotherapeutic adjuvant; an immunopotentiator; and a method for preparing a T cell population wherein the ratio of memory T cells is increased, said method comprising using the compound of formula (I).

公开(公告)号：US10195258B2

公开(公告)日：2019-02-05

申请号：US14166954

申请日：2014-01-29

Applicant: NITTO DENKO CORPORATION ,  OSAKA UNIVERSITY

Inventor： Yoshiki Maeda ,  Katsuyuki Okubo ,  Daisuke Asari ,  Arimichi Okazaki ,  Takuya Shishido ,  Mitsuhiko Hori ,  Haruo Sugiyama

IPC: A61K39/00 ,  A61K9/70

Abstract: The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising: a support, an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of: (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy.

公开(公告)号：US10206985B2

公开(公告)日：2019-02-19

申请号：US14166970

申请日：2014-01-29

Applicant: NITTO DENKO CORPORATION ,  OSAKA UNIVERSITY

Inventor： Daisuke Asari ,  Kyohei Matsushita ,  Arimichi Okazaki ,  Yoshiki Maeda ,  Katsuyuki Okubo ,  Mitsuhiko Hori ,  Haruo Sugiyama

IPC: A61K39/00 ,  A61K9/00

Abstract: The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.